Company Active PLC

Company profile

Rua Life Sciences PLC

Home - Rua Life Sciences

The RUA Life Sciences group was created in April 2020 when AorTech International plc acquired RUA Medical Devices Ltd.

CRN
SC170071
Founded
1996
Age
29

Overview

Legal name
RUA LIFE SCIENCES PLC
Region
Scotland
Registered address
2 DRUMMOND CRESCENT
RIVERSIDE BUSINESS PARK
IRVINE
AYRSHIRE
UNITED KINGDOM
KA11 5AN
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

Rua Life Sciences PLC
No active corporate controller recorded.

Company events

Reference milestones and recent Companies House filing stream events.

10 events
31 Mar
2027

Accounts due

Accounts Due

Next accounts due date

29 Oct
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

23 Mar
2026

Resolution

Resolution

RESOLUTIONS | Transaction WUVZQTJEM0VhZGlxemtjeA | Paper/PDF filed

Published 24 Mar 2026 23:53

15 Oct
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

30 Sep
2025

Accounts filed

Accounts

Last accounts made up date

05 Nov
2024

Change Account Reference Date Company Current Extended

Accounts Awaiting analysis

AA01 | Transaction MzQ0MjA2ODI0NGFkaXF6a2N4

Published 05 Nov 2024 04:43

23 Oct
2024

Accounts With Accounts Type Group

Accounts PDF pending

AA | Transaction MzQ0MDUwNjQ4NWFkaXF6a2N4 | Paper/PDF filed

Published 24 Oct 2024 07:00

15 Oct
2024

Confirmation Statement With No Updates

Confirmation-statement

CS01 | Transaction MzQzOTUyNDY4N2FkaXF6a2N4

Published 15 Oct 2024 08:55

29 Aug
2024

Resolution

Resolution

RESOLUTIONS | Transaction WURBRDFFS1phZGlxemtjeA | Paper/PDF filed

Published 31 Aug 2024 07:00

21 Nov
1996

Incorporated

Inception

Company registered at Companies House

Public funding

1 award
First funded
2022
Funded years
2022
Age at first award
25 years

Projects

2022 Collaborative R&D Lead participant

Early Feasibility Study for Critical Limb Ischaemia intervention device into US Markets

1 Jan 2022 to 31 Mar 2022

Awarded
£18,540
Total cost £26,486

The project is designed to establish the commercial viability and potential for market launch of a novel vascular graft specifically designed to improve graft durability and the outcomes for patients requiring surgical intervention for critical limb ischemia. The graft will utilise the proven biocompatibility and non-thrombogenic nature of Elast-Eon toget...

Product types

Collaborative R&D